Bill · S. 5383· Senate(119-S-5383)
End Gas Station Heroin Act
- Introduced
- 8/8/2026
- Last activity
- 8/8/2026 — Read twice and referred to the Committee on the Judiciary.
- Sponsored by
- Bernie Moreno
- Cosponsors
- - 1 - 0
- Introduced
- In Committee
What this bill would do
The "End Gas Station Heroin Act" updates the Controlled Substances Act to classify certain substances as Schedule I. It adds MGM-15 and MGM-16 to Schedule I and sets specific concentration limits for synthetic 7-hydroxymitragynine and mitragynine pseudoindoxyl. The bill targets the manufacture and commercial distribution of emerging synthetic opioids. It specifically excludes simple possession or personal use from criminal or civil enforcement.
Yes· 3 of 11
Does this do more about addiction and overdose deaths?+8
Targets the distribution of potent synthetic opioids to mitigate public health risks.
Does this give people more protection from unfair business practices?+5
Protects consumers from dangerous synthetic opioids marketed as 'gas station heroin'.
Would children be better off under this?+4
Reduces availability of dangerous synthetic opioids in commercial distribution.
The opposite
Would business owners be better off under this?-2
Increases legal risk for those manufacturing or distributing synthetic analogs.
Who it would affect, and how
Potential Positive Impacts for People
-
Protection from "Gas Station Heroin": The bill expands enforcement against the manufacture, importation, exportation, and distribution of emerging synthetic opioids, which are commonly known as gas station heroin (Section 3).
-
Protection for Personal Users: Individuals will not be subject to criminal or civil enforcement based solely on the purchase, receipt, simple possession, or personal use of a covered emerging synthetic opioid (Section 3(b) and 3(e)).
-
Exemptions for Natural Products: Natural kratom products are not classified as Schedule I if they stay below specific concentration thresholds (1 mg per gram for solids or 1 mg per milliliter for liquids) and do not exceed 1 part per 100 parts mitragynine by mass (Section 2(B)).
-
Support for Science and Medicine: The bill excludes substances used for legitimate scientific, medical, forensic, analytical, or law-enforcement purposes from being labeled as covered emerging synthetic opioids (Section 3(g)(4)).
Potential Negative Impacts for People
-
Stricter Penalties for Distribution: People involved in the knowing or intentional manufacture, distribution, or possession with intent to distribute covered emerging synthetic opioids will be treated as if they are dealing with Schedule I controlled substances (Section 3(a)).
-
Restrictions on Manufactured Alkaloids: Any 7-hydroxymitragynine or mitragynine pseudoindoxyl produced through manufacturing processes, such as being concentrated or isolated, is ineligible for the kratom exemption and would be treated as a Schedule I substance (Section 2(C)).
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Hover a score for the reason it gave.
- Demographic And Interest Groups
- Good For Children+4Good For High Income Households+4Good For Low Income Households+4Good For Middle Aged+4Good For Middle Class Households+4Good For Seniors+4Good For Young Adults+4Good For Business Owners-2
- Healthcare
- Improves Opioid Crisis Response+8
- Economy And Finance
- Improves Consumer Protection+5
- Governance And Ideology
- Increases Federal Power+3
- Social Issues And Justice
- Improves Criminal Sentencing Reform+2
- 9/29/2026
- 1 Cosponsor added.
- 8/8/2026
- Read twice and referred to the Committee on the Judiciary.
- Introduced in Senate
One bill Congress.gov lists as related to this one — companions in the other chamber, earlier versions, and bills this one absorbed or was folded into.
Mike LeeRepublican · Utah